Status:

COMPLETED

Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma

Lead Sponsor:

AstraZeneca

Collaborating Sponsors:

Amgen

Conditions:

Severe Asthma

Eligibility:

All Genders

12-80 years

Phase:

PHASE3

Brief Summary

This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled ...

Detailed Description

This is open-label, single arm study designed to evaluate the safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional as...

Eligibility Criteria

Inclusion

  • Age. 12-80 Documented physician-diagnosed asthma for at least 12 months Subjects who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 12 months.
  • Documented treatment with a total daily dose of either medium or high dose ICS (≥ 500 µg fluticasone propionate dry powder formulation equivalent total daily dose) for at least 3 months.
  • At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.
  • Documented history of at least 1 asthma exacerbation events within 12 months. ACQ-6 score ≥1.5 at screening or on day of registration.

Exclusion

  • Pulmonary disease other than asthma. History of cancer. History of a clinically significant infection. Current smokers or subjects with smoking history ≥10 pack-yrs. History of chronic alcohol or drug abuse within 12 months. Hepatitis B, C or HIV. Pregnant or breastfeeding. History of anaphylaxis following any biologic therapy. Subject randomized in the current study or previous tezepelumab studies

Key Trial Info

Start Date :

June 10 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 18 2021

Estimated Enrollment :

65 Patients enrolled

Trial Details

Trial ID

NCT04048343

Start Date

June 10 2019

End Date

March 18 2021

Last Update

June 1 2022

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Research Site

Chūōku, Japan, 103-0022

2

Research Site

Chūōku, Japan, 104-0031

3

Research Site

Sagamihara-shi, Japan, 228-0815

4

Research Site

Shinagawa-ku, Japan, 140-8522

Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma | DecenTrialz